This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This JAM3 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 261-295 amino acids from the C-terminal region of human JAM3.
Recent
JAM3
Reactivity: Human
ELISA
Host: Goat
Polyclonal
unconjugated
Application Notes
WB: 1:1000
Restrictions
For Research Use only
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Expiry Date
6 months
Santoso, Sachs, Kroll, Linder, Ruf, Preissner, Chavakis: "The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1." in: The Journal of experimental medicine, Vol. 196, Issue 5, pp. 679-91, (2002) (PubMed).
Phillips, Renforth, Spalluto, Hearn, Curtis, Craven, Havarani, Clement-Jones, English, Stumper, Salmon, Hutchinson, Jackson, Wilson: "Narrowing the critical region within 11q24-qter for hypoplastic left heart and identification of a candidate gene, JAM3, expressed during cardiogenesis." in: Genomics, Vol. 79, Issue 4, pp. 475-8, (2002) (PubMed).
Arrate, Rodriguez, Tran, Brock, Cunningham: "Cloning of human junctional adhesion molecule 3 (JAM3) and its identification as the JAM2 counter-receptor." in: The Journal of biological chemistry, Vol. 276, Issue 49, pp. 45826-32, (2001) (PubMed).
Participates in cell-cell adhesion. It is a counter- receptor for ITGAM, mediating leukocyte-platelet interactions and is involved in the regulation of transepithelial migration of polymorphonuclear neutrophils (PMN). The soluble form is a mediator of angiogenesis.